BioStock: Fast Track designation facilitates development of Oncoinvent’s Radspherin
The FDA has granted Fast Track to Oncoinvent for its radiopharmaceutical Radspherin as a treatment for peritoneal metastases originating from ovarian cancer. This designation will facilitate the candidate’s clinical development, with the next step being a phase IIb trial first in ovarian cancer patients, then in colorectal cancer patients.Read the full article at biostock.se : https://www.biostock.se/en/2024/06/fast-track-designation-facilitates-development-of-oncoinvents-radspherin/ This is a press release from BioStock - Connecting Innovation & Capital.